{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&q=mCRC", "query": { "q": "mCRC", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&q=mCRC&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T05:18:32.134Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05839951", "title": "An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Colorectal Cancer (mCRC)" ], "interventions": [ { "name": "Regorafenib (BAY73-4506, Stivarga®)", "type": "DRUG" }, { "name": "TAS-102 (trifluridine and tipiracil, Lonsurf®)", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 818, "start_date": "2023-04-24", "completion_date": "2025-04-30", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-07-24T05:18:32.134Z", "location_count": 1, "location_summary": "Whippany, New Jersey", "locations": [ { "city": "Whippany", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05839951" }, { "nct_id": "NCT00856375", "title": "NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "NKTR-102", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2008-12", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2021-07-12", "last_synced_at": "2026-07-24T05:18:32.134Z", "location_count": 9, "location_summary": "Peoria, Arizona • Burbank, California • Los Angeles, California + 6 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Vallejo", "state": "California" }, { "city": "Centralia", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00856375" }, { "nct_id": "NCT06492291", "title": "Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Enlicitide Decanoate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3000, "start_date": "2024-08-05", "completion_date": "2028-10-13", "has_results": false, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-07-24T05:18:32.134Z", "location_count": 52, "location_summary": "Daphne, Alabama • Foley, Alabama • Phoenix, Arizona + 48 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Foley", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06492291" }, { "nct_id": "NCT02448810", "title": "Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "BAX69 + infusional 5-FU/LV", "type": "BIOLOGICAL" }, { "name": "BAX69 + panitumumab", "type": "BIOLOGICAL" }, { "name": "BAX69 + 5-FU/LV", "type": "BIOLOGICAL" }, { "name": "Standard of Care", "type": "DRUG" }, { "name": "Standard of Care", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2015-06-15", "completion_date": "2017-02-15", "has_results": true, "last_update_posted_date": "2021-05-25", "last_synced_at": "2026-07-24T05:18:32.134Z", "location_count": 12, "location_summary": "Port Saint Lucie, Florida • Joliet, Illinois • Goshen, Indiana + 9 more", "locations": [ { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Joliet", "state": "Illinois" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Rockville", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02448810" }, { "nct_id": "NCT01931150", "title": "Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cetuximab-induced Papulopustular (Acneiform) Rash Who Have", "Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Topical Dapsone 5% Gel", "type": "DRUG" }, { "name": "Moisturizer", "type": "OTHER" }, { "name": "oral antibiotics", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2013-08", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-01-13", "last_synced_at": "2026-07-24T05:18:32.134Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01931150" }, { "nct_id": "NCT05425940", "title": "Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "XL092", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 901, "start_date": "2022-09-07", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-07-24T05:18:32.134Z", "location_count": 45, "location_summary": "Jonesboro, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more", "locations": [ { "city": "Jonesboro", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05425940" }, { "nct_id": "NCT07224724", "title": "Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer Liver Metastases (CRLM)", "Metastatic Colorectal Carcinoma (mCRC)" ], "interventions": [ { "name": "EXELION", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2024-06-01", "completion_date": "2028-06-18", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-07-24T05:18:32.134Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07224724" }, { "nct_id": "NCT03798626", "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Gastroesophageal Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "Gevokizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Modified FOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 167, "start_date": "2019-05-22", "completion_date": "2025-02-05", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-07-24T05:18:32.134Z", "location_count": 3, "location_summary": "Los Angeles, California • St Louis, Missouri • Nashville, Tennessee", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03798626" }, { "nct_id": "NCT07042685", "title": "Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer (CRC)" ], "interventions": [ { "name": "Fruquintinib Combined With Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2026-01-27", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-07-24T05:18:32.134Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07042685" }, { "nct_id": "NCT03271047", "title": "Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MSS", "RAS-mutant Colorectal Cancer" ], "interventions": [ { "name": "binimetinib", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2017-10-18", "completion_date": "2021-02-25", "has_results": true, "last_update_posted_date": "2022-01-04", "last_synced_at": "2026-07-24T05:18:32.134Z", "location_count": 33, "location_summary": "Los Angeles, California • Santa Monica, California • Newark, Delaware + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT03271047" } ] }